Switch theme
Sign up to access all valuation multiples
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company’s portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.
2012
38
LTM Revenue $0.7M
Last FY EBITDA -$176M
$117M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Cidara Therapeutics has a last 12-month revenue (LTM) of $0.7M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Cidara Therapeutics achieved revenue of $1.3M and an EBITDA of -$176M.
Cidara Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Cidara Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $0.7M | XXX | $1.3M | XXX | XXX | XXX |
| Gross Profit | $0.4M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 59% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$176M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -13794% | XXX | XXX | XXX |
| EBIT | -$159M | XXX | -$176M | XXX | XXX | XXX |
| EBIT Margin | -21232% | XXX | -13812% | XXX | XXX | XXX |
| Net Profit | -$151M | XXX | -$170M | XXX | XXX | XXX |
| Net Margin | -20255% | XXX | -13320% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Cidara Therapeutics's stock price is $22.
Cidara Therapeutics has current market cap of $282M, and EV of $117M.
See Cidara Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $117M | $282M | XXX | XXX | XXX | XXX | $-18.89 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Cidara Therapeutics has market cap of $282M and EV of $117M.
Cidara Therapeutics's trades at 91.5x EV/Revenue multiple, and -0.7x EV/EBITDA.
Equity research analysts estimate Cidara Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Cidara Therapeutics has a P/E ratio of -1.9x.
See valuation multiples for Cidara Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $282M | XXX | $282M | XXX | XXX | XXX |
| EV (current) | $117M | XXX | $117M | XXX | XXX | XXX |
| EV/Revenue | 156.0x | XXX | 91.5x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -0.7x | XXX | XXX | XXX |
| EV/EBIT | -0.7x | XXX | -0.7x | XXX | XXX | XXX |
| EV/Gross Profit | 263.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.9x | XXX | -1.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -0.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCidara Therapeutics's revenue per employee in the last FY averaged $34K, while opex per employee averaged $4.7M for the same period.
Cidara Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Cidara Therapeutics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Cidara Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -13794% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $34K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $4.7M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 12295% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 13912% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cidara Therapeutics acquired XXX companies to date.
Last acquisition by Cidara Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Cidara Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Cidara Therapeutics founded? | Cidara Therapeutics was founded in 2012. |
| Where is Cidara Therapeutics headquartered? | Cidara Therapeutics is headquartered in United States of America. |
| How many employees does Cidara Therapeutics have? | As of today, Cidara Therapeutics has 38 employees. |
| Who is the CEO of Cidara Therapeutics? | Cidara Therapeutics's CEO is Dr. Jeffrey Stein, PhD. |
| Is Cidara Therapeutics publicy listed? | Yes, Cidara Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Cidara Therapeutics? | Cidara Therapeutics trades under CDTX ticker. |
| When did Cidara Therapeutics go public? | Cidara Therapeutics went public in 2015. |
| Who are competitors of Cidara Therapeutics? | Similar companies to Cidara Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Cidara Therapeutics? | Cidara Therapeutics's current market cap is $282M |
| What is the current revenue of Cidara Therapeutics? | Cidara Therapeutics's last 12 months revenue is $0.7M. |
| What is the current EV/Revenue multiple of Cidara Therapeutics? | Current revenue multiple of Cidara Therapeutics is 156.0x. |
| Is Cidara Therapeutics profitable? | Yes, Cidara Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
